Neuland Laboratories Limited has announced its financial results for the fiscal year ended March 31, 2026. The company delivered a robust performance, reporting a total income of ₹2,053.1 crore and an EBITDA of ₹603.4 crore. Management emphasized strong business visibility driven by commercial and near-commercial molecules, while maintaining a strategic focus on future growth through ongoing investments in peptide manufacturing and a new state-of-the-art R&D centre.
Annual Financial Highlights
Neuland Laboratories concluded FY26 on a strong note, reflecting the company’s operational excellence. For the quarter ended March 31, 2026 (Q4FY26), the company reported a total income of ₹788.7 crore, marking a significant year-on-year increase. The EBITDA for the quarter stood at ₹319.4 crore with a strong margin of 40.5%. Profit after tax for the quarter reached ₹212.5 crore, demonstrating consistent growth compared to previous periods.
Strategic Outlook and Expansion
The company’s leadership attributed this growth to disciplined execution and a robust portfolio of pharmaceutical products. Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, noted that business visibility remains high, supported by the company’s ongoing focus on high-quality, sustainable projects.
Investment in Future Capabilities
To sustain its momentum, Neuland Laboratories is actively investing in long-term infrastructure. Key foundation projects, including expanded Peptide Manufacturing capabilities and the development of a new R&D Centre, are proceeding according to plan. These initiatives are designed to align with the company’s broader business development strategy, ensuring they remain well-positioned for growth beyond the current fiscal horizon.
Source: BSE
